🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Gland Pharma Limited GLAND NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.glandpharma.com

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

READ MORE ›
₹2,250.00
+43.90% 1Y

Market & Price

Market Cap
₹37,070.19 Cr
Current Price
₹2,250.00
High / Low (52W)
₹2,334.00 / ₹1,563.63
Beta
0.38

Valuation

Stock P/E
36.10
Industry PE
37.60
Forward P/E
24.68
PEG Ratio
-
Book Value
₹580.47
Price to Book
3.88
P/S
5.76
EV/EBITDA
20.81
Dividend Yield
0.89%

Profitability & Returns

ROCE
13.74%
ROE
10.53%
ROA
6.35%
Profit Margin
15.97%
Op Margin
23.20%
EPS (Latest Qtr)
₹22.23
EPS (TTM)
₹62.32

Balance Sheet & Liquidity

Debt/Equity
2.74
Quick Ratio
3.31
Current Ratio
4.68
Debt
₹283.59 Cr
Total Assets
₹12,510.85 Cr
Current Assets
₹7,526.78 Cr
Working Capital
₹5,918.38 Cr

Ownership

Promoter Holding
51.83%
Chg in Prom Hold
0.00%
FII / Inst Holding
36.30%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹33,913.58 Cr
Total Revenue (TTM)
₹6,430.65 Cr
EBITDA
₹1,629.54 Cr
Free Cash Flow
₹504.15 Cr
Operating Cash Flow
₹1,031.39 Cr
Shares Outstanding
₹16.48 Cr
Gross Margin
61.97%
Payout Ratio
28.90%

Growth (CAGR)

Revenue 5Y
21.43%
Profit 5Y
9.57%
Revenue (YoY)
22.30%
Earnings (YoY)
96.40%

PROS

  • Compounding revenue at 21.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GLAND Gland Pharma Limited NIFTY_SMALLNSEPHARMA 2,250.00 36.10 ₹37,070.19 Cr 0.89% 13.74% 10.53% 21.43% 9.57%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 1,384.05 Cr1,424.91 Cr1,505.62 Cr1,695.36 Cr1,742.79 Cr
Cost of Revenue 462.71 Cr487.95 Cr521.13 Cr576.65 Cr591.33 Cr
Gross Profit 921.34 Cr936.96 Cr984.49 Cr1,118.71 Cr1,151.46 Cr
Operating Expenses 657.71 Cr685.20 Cr717.78 Cr791.48 Cr747.10 Cr
Operating Income 263.63 Cr251.75 Cr266.71 Cr327.23 Cr404.36 Cr
EBITDA 418.45 Cr391.54 Cr425.29 Cr473.70 Cr624.49 Cr
Interest Expense 22.82 Cr7.45 Cr11.50 Cr3.93 Cr10.03 Cr
Pretax Income 299.30 Cr288.33 Cr312.74 Cr362.13 Cr505.80 Cr
Tax Provision 94.61 Cr101.79 Cr97.26 Cr100.65 Cr139.12 Cr
Net Income 204.69 Cr186.54 Cr215.48 Cr261.48 Cr366.68 Cr
Diluted EPS 12.4211.3213.0815.8722.23

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -3,591.86 Cr5,641.73 Cr5,616.50 Cr6,430.65 Cr
Cost of Revenue -1,685.43 Cr2,173.09 Cr2,090.38 Cr2,242.93 Cr
Gross Profit -1,906.43 Cr3,468.64 Cr3,526.12 Cr4,187.72 Cr
Operating Expenses -1,036.32 Cr2,472.55 Cr2,635.07 Cr2,981.84 Cr
Operating Income -870.11 Cr996.09 Cr891.05 Cr1,205.88 Cr
EBITDA -1,207.61 Cr1,498.90 Cr1,482.53 Cr1,921.53 Cr
Interest Expense -6.29 Cr21.79 Cr42.00 Cr33.28 Cr
Pretax Income -1,054.58 Cr1,132.54 Cr1,062.66 Cr1,464.58 Cr
Tax Provision -273.54 Cr360.08 Cr364.13 Cr437.26 Cr
Net Income -781.04 Cr772.46 Cr698.53 Cr1,027.32 Cr
Diluted EPS -47.4346.8942.4062.28

Compounded Sales Growth

5 Years:21.43%
1 Year:22.30%

Compounded Profit Growth

5 Years:9.57%
1 Year:96.40%

Stock Price Performance

1 Year:+43.90%
6 Months:+25.63%
3 Months:+24.83%
1 Month:+28.51%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -8,777.53 Cr10,661.25 Cr11,224.92 Cr12,510.85 Cr
Current Assets -6,900.81 Cr5,645.15 Cr6,782.94 Cr7,526.78 Cr
Cash & Equivalents -1,908.89 Cr357.09 Cr2,556.19 Cr3,359.11 Cr
Inventory -1,945.30 Cr1,655.24 Cr1,685.22 Cr1,743.89 Cr
Receivables -871.39 Cr1,558.69 Cr1,516.53 Cr1,891.38 Cr
Total Liabilities -818.81 Cr1,937.40 Cr2,074.18 Cr2,152.90 Cr
Current Liabilities -729.13 Cr1,398.36 Cr1,564.85 Cr1,608.40 Cr
Long Term Debt -3.26 Cr106.54 Cr77.66 Cr69.92 Cr
Total Debt -4.45 Cr372.17 Cr313.73 Cr283.59 Cr
Total Equity -7,958.72 Cr8,723.84 Cr9,150.74 Cr10,357.95 Cr
Shares Outstanding -16.47 Cr16.47 Cr16.48 Cr16.48 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -363.97 Cr996.80 Cr914.73 Cr1,031.39 Cr
Investing Cash Flow -1,208.19 Cr-1,756.91 Cr1,704.74 Cr137.73 Cr
Financing Cash Flow -14.92 Cr-799.42 Cr-433.48 Cr-416.97 Cr
Capital Expenditure --223.12 Cr-398.26 Cr-394.17 Cr-494.43 Cr
Free Cash Flow -140.85 Cr598.54 Cr520.56 Cr536.96 Cr
Net Change in Cash -1,587.08 Cr-1,559.53 Cr2,185.99 Cr752.14 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -53.1%61.5%62.8%65.1%
Operating Margin % -24.2%17.7%15.9%18.8%
Net Margin % -21.7%13.7%12.4%16.0%
ROE % -9.8%8.9%7.6%9.9%
ROCE % -10.8%10.8%9.2%11.1%

Shareholding Pattern

Insiders
51.83%
Institutions
36.30%
Public Float
75.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GLAND

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space